#USA #Charlotte #Immunic #Vidofludimus #Neurologic Diseases

Immunic's Upcoming Conferences Highlighting Neurologic Innovations

Immunic, Inc. (Nasdaq: IMUX), a leading late-stage biotechnology company known for its cutting-edge oral therapies for neurologic diseases, has announced its participation in two prominent investor and medical conferences this May. This initiative underscores the company's commitment to advancing treatments in the field of neurology and engaging with both investors and industry professionals.

Conference Schedule

Bio€quity Europe

• - Dates: May 4-6 and May 12-13
• - Location: Prague, Czech Republic and Virtual

Immunic’s Chief Executive Officer, Daniel Vitt, Ph.D., and Jessica Breu, Vice President of Investor Relations and Communications, will be attending this influential conference. They will host one-on-one meetings with investors, providing a platform to discuss Immunic's ongoing projects and future directions. Interested parties can arrange a meeting through the Bio€quity Europe conference portal or contact Jessica directly at [email protected].

Consortium of Multiple Sclerosis Centers (CMSC) Annual Meeting

• - Dates: May 27-29
• - Location: Charlotte, NC

At the CMSC Annual Meeting, members of Immunic’s leadership, medical, and preclinical teams will be present. Notably, Immunic will showcase innovative research findings through a late-breaking poster presentation, alongside two additional poster sessions, all of which are crucial in discussing the efficacy and safety of their primary treatment.

Presentations Highlights

The presentations during the CMSC will include:
1. Late-Breaking Poster:
- Title: Novel Unified Statistical Analyses for Confirmed Disability Changes In Multiple Sclerosis for Capturing Possible Neuroprotective Effects
- Presenting Author: James Myles, Global Head of Biostatistics
- Session Date: May 28, 2026
- Location: Exhibit Hall
2. Poster Presentations:
- Title: Effect of Vidofludimus Calcium, a Direct Nurr1 Activator and Selective DHODH Inhibitor, on Patient-Reported Outcomes (PRO) in Progressive MS Data from Phase 2 CALLIPER Trial
- Presenting Author: Julie Korich, Ph.D., Senior Medical Director
- Location: Exhibit Hall B
- Title: Safety and Tolerability of Vidofludimus Calcium, a Direct Nurr1 Activator and Selective DHODH Inhibitor Data from Phase 2 CALLIPER Trial
- Presenting Author: Alex Lublin, Ph.D., Senior Medical Director
- Location: Exhibit Hall B
Both posters aim to address findings related to Immunic’s lead development program, vidofludimus calcium, which targets multiple sclerosis.

About Immunic, Inc.

Immunic, Inc. is at the forefront of developing novel oral therapies for neurologic disorders. Their flagship program, vidofludimus calcium (IMU-838), is currently undergoing phase 3 clinical trials aimed at treating relapsing multiple sclerosis. With expectations to release top-line data by the end of 2026, early trials have demonstrated significant therapeutic potential across different forms of multiple sclerosis and other related disorders.

Vidofludimus calcium operates as a unique agent by providing neuroprotective benefits while also delivering anti-inflammatory and anti-viral effects. The company is also working on other development programs like IMU-856 and IMU-381, focused on expanding its therapeutic arsenal against neurodegenerative and autoimmune diseases.

For more details about their initiatives and research findings, visit Immunic's Website.

Cautionary Note

This announcement contains forward-looking statements that reflect Immunic's current plans and objectives. Uncertainties and risks associated with drug development, market conditions, and clinical trials may affect the realization of these plans. Stakeholders are encouraged to approach these forward-looking statements with caution, keeping in mind the volatile nature of biotechnology advancements.

Conclusion

Immunic’s participation in these leading conferences presents a significant opportunity for the company to engage with key stakeholders and to advance discussions surrounding innovative treatments for neurologic diseases, signaling a promising future for those impacted by such conditions.